Complete financial analysis of TOT BIOPHARM International Company Limited (1875.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TOT BIOPHARM International Company Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Shoei Yakuhin Co.,Ltd. (3537.T) Income Statement Analysis – Financial Results
- Synsam AB (publ) (SYNSAM.ST) Income Statement Analysis – Financial Results
- Hudson Resources Inc. (HUD.V) Income Statement Analysis – Financial Results
- G8 Education Limited (GEM.AX) Income Statement Analysis – Financial Results
- PVR INOX Limited (PVRINOX.NS) Income Statement Analysis – Financial Results
TOT BIOPHARM International Company Limited (1875.HK)
About TOT BIOPHARM International Company Limited
TOT BIOPHARM International Company Limited, an investment holding company, engages in the research and development, manufacture, and marketing of anti-tumor drugs in the People's Republic of China. The company's principal drug candidate is TAB008 for the treatment of non-squamous non-small-cell lung cancer metastatic colorectal cancer, glioblastoma multiforme, ovarian cancer, cervical cancer, and hepatocellular carcinoma. It also offers TOZ309 for malignant brain tumor. Further, the company develops TAA013 for HER2+ breast cancer which is under Phase III clinical trial; TAE020 which is under preclinical trial for acute myeloid leukemia; TAB014 for wet age-related macular degeneration and is under Phase II clinical trial. In addition, it develops TAY018 for non-Hodgkin's lymphoma, myelodysplastic syndrome, acute myelogenous leukemia, and solid tumors; TAC020 for various solid tumors; TEP118 for biliary cancer, gallbladder tumors, metastatic cancer, non-small-cell lung cancer (NSCLC), and gastric cancer; TOM312 for cancer and HIV-associated cachexia; TIC318 for epithelial-derived ovarian cancer, small-cell lung cancer, head and neck squamous cell carcinoma, testicular tumors, malignant lymphoma, cervical cancer, bladder cancer, and NSCLC; TVP211 and TID214 for solid tumors; and TIO217 for gastrointestinal tumors. TOT BIOPHARM International Company Limited was incorporated in 2009 and is headquartered in Suzhou, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 780.63M | 442.18M | 76.33M | 22.49M | 45.31M | 39.22M | 51.61M |
| Cost of Revenue | 206.64M | 71.56M | 48.85M | 6.96M | 11.32M | 5.98M | 4.24M |
| Gross Profit | 573.99M | 370.62M | 27.47M | 15.53M | 33.99M | 33.24M | 47.37M |
| Gross Profit Ratio | 73.53% | 83.82% | 36.00% | 69.05% | 75.02% | 84.75% | 91.78% |
| Research & Development | 103.89M | 151.17M | 214.70M | 235.20M | 191.08M | 188.65M | 105.94M |
| General & Administrative | 68.31M | 62.59M | 56.34M | 46.86M | 95.09M | 31.21M | 9.17M |
| Selling & Marketing | 441.02M | 203.95M | 22.85M | 25.95M | 31.54M | 38.94M | 28.89M |
| SG&A | 509.33M | 266.54M | 79.19M | 72.81M | 126.64M | 70.14M | 38.06M |
| Other Expenses | -6.17M | 500.00K | 262.00K | 394.00K | -12.22M | 11.05M | 9.72M |
| Operating Expenses | 607.05M | 409.45M | 282.93M | 305.27M | 305.49M | 269.85M | 153.72M |
| Cost & Expenses | 813.69M | 481.01M | 331.78M | 312.23M | 316.81M | 275.83M | 157.96M |
| Interest Income | 2.97M | 2.27M | 969.00K | 1.88M | 1.68M | 727.00K | 470.00K |
| Interest Expense | 5.18M | 6.60M | 2.47M | 1.71M | 2.29M | 2.40M | 277.00K |
| Depreciation & Amortization | 43.03M | 38.04M | 34.24M | 32.08M | 27.35M | 15.66M | 13.49M |
| EBITDA | 10.45M | -5.41M | -224.51M | -254.71M | -240.07M | -221.42M | -134.92M |
| EBITDA Ratio | 1.34% | -0.76% | -286.62% | -1,134.04% | -529.86% | -564.57% | -179.76% |
| Operating Income | -33.06M | -39.08M | -259.70M | -288.67M | -271.50M | -237.18M | -105.97M |
| Operating Income Ratio | -4.24% | -8.84% | -340.26% | -1,283.50% | -599.23% | -604.75% | -205.33% |
| Total Other Income/Expenses | -4.70M | -10.97M | -1.52M | 174.00K | -29.70M | -31.09M | -42.72M |
| Income Before Tax | -37.76M | -50.05M | -261.22M | -288.50M | -299.30M | -268.26M | -148.69M |
| Income Before Tax Ratio | -4.84% | -11.32% | -342.24% | -1,282.73% | -660.59% | -684.01% | -288.11% |
| Income Tax Expense | 1.00K | -2.60M | 2.46M | 4.29M | 31.88M | -29.25M | 88.00K |
| Net Income | -37.76M | -49.92M | -261.22M | -288.50M | -331.18M | -268.26M | -148.69M |
| Net Income Ratio | -4.84% | -11.29% | -342.24% | -1,282.73% | -730.95% | -684.01% | -288.11% |
| EPS | -0.05 | -0.08 | -0.46 | -0.51 | -0.99 | -0.47 | -0.26 |
| EPS Diluted | -0.05 | -0.08 | -0.46 | -0.51 | -0.99 | -0.47 | -0.26 |
| Weighted Avg Shares Out | 725.20M | 639.31M | 573.36M | 570.33M | 335.65M | 570.00M | 570.00M |
| Weighted Avg Shares Out (Dil) | 725.20M | 639.31M | 573.36M | 570.33M | 335.65M | 570.00M | 570.00M |
Source: https://incomestatements.info
Category: Stock Reports